Alpine Immune Sciences, Inc.
ALPN

$4.46 B
Marketcap
$64.97
Share price
Country
$0.01
Change (1 day)
$65.00
Year High
$8.33
Year Low
Categories

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

marketcap

Stock split history for Alpine Immune Sciences, Inc. (ALPN)

Alpine Immune Sciences, Inc. stock (symbol: ALPN) underwent a total of 1 stock splits.
The most recent stock split occured on Jul 25, 2017.

Annual Revenue

Date Splite Multiple
2017-07-25 1:4 1